Owner and operator of an innovation-driven biotechnology company intended to develop drugs targeting membrane proteins. The company's services mainly focus on discovering and developing therapeutic drugs and technologies to enable discovery and development of drugs targeting membrane proteins including G protein-coupled receptors (GPCRs) and ion channels through the application of its enabled membrane proteins technology platform, enabling clients to have access to tool receptors for antibody discovery and a technical service through the generation of enabled membrane proteins.